CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
93.99
-1.72 (-1.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close95.71
Open95.65
Bid93.90 x 1000
Ask96.23 x 800
Day's Range93.41 - 96.05
52 Week Range58.59 - 98.97
Volume4,651,491
Avg. Volume4,111,150
Market Cap66.615B
Beta (3Y Monthly)1.50
PE Ratio (TTM)12.85
EPS (TTM)7.32
Earnings DateOct 23, 2019 - Oct 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est96.80
Trade prices are not sourced from all markets
  • 5 Healthcare Stocks to Buy for Healthy Dividends
    InvestorPlace

    5 Healthcare Stocks to Buy for Healthy Dividends

    These days, the healthcare stocks are looking pretty healthy compared to stocks in other spaces. Despite political pressures about lowering costs, "Medicare for All" and importing drugs, the sector has been riding high on a wave of optimism and growth. Demand for various healthcare solutions continues to rise as our aging population simply requires more. And that story is pretty much the same across the world.Even better is that recent market volatility has sent many investors into healthcare stocks for their high cash flows and strong dividend potential. Many healthcare stocks have long been dividend champions -- offering both high initial yields and overall strong dividend growth. For investors looking for income and the ability to keep that income rising over the long haul, healthcare stocks can't be beaten.The best part is that the sector's overall growth rates don't seem to be slowing anytime soon. That makes healthcare a prime destination for long-term investors.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Own Through a Global Recession So, which healthcare stocks have great growth trajectories and can pay you plenty of dividends for the long-term? Here's a prescription for five that fit the bill. Healthcare Stocks to Buy Today: Baxter International Inc (BAX)Source: Shutterstock Dividend Yield: 1.1%If you've ever been in the hospital, there's a good chance that you've used products made by Baxter International (NYSE:BAX). That bag of Ringer's solution connected to your I.V. is one of its most famous products. However, Baxter's catalog spans not only all the stuff needed for running intravenous drugs, including the tubing, pumps and connectors, but also a variety of premixed drugs and therapies as well.Those bags of basic Ringer's solution, tubes, and other hospital must-haves create plenty of repeat orders from facility administrators. You can't really operate a hospital without them. As a result, BAX ships more than one million sterile units each day.This niche has served BAX well over the years and has made it a profit machine. Last quarter, Baxter saw a 4% jump to its operational revenues and managed to see an adjusted profit gain of 16% year-over-year. This follows great results for the first quarter of 2019 and the fourth quarter of last year. These wins plus its recent top-notch results allowed management to boost its full-year 2019 earnings guidance.And there's a good chance that it'll beat even those better numbers. BAX has several new approved products hitting the market this year, including the only intravenous insulin product Myxredlin and new nutritional products. Meanwhile, Baxter is poised to see growth from increased home dialysis patients.With strong revenues already in the tank and future growth on the horizon, BAX should be able to keep growing its dividend as well. While it only yields 1.1% today, that payout has increased by 156% over the last 10 years. Bristol-Myers Squibb (BMY)Source: Shutterstock Dividend Yield: 3.43%The major pharmaceuticals are some of the best healthcare stocks to comb for dividends and Bristol-Myers Squibb (NYSE:BMY) could be one of the best. The firm has a huge portfolio of drugs, including many blockbusters than produce ample amounts of cash flow. That plus its 3.43% yield is worth the price of admission alone. However, the real reason to buy BMY is its status as a major cancer fighter.That title comes from blockbuster cancer drug Opdivo. The oncology medicine pulls in more than $2 billion in quarterly revenues for the firm and continues to see growth. Last quarter, sales of Opdivo managed to grow by 12%. Meanwhile, Bristol-Meyers continues to pivot the success of Opdivo in other directions as well. And we can't forget the other cancer fighters under its umbrella -- such as Yervoy -- which also grew by double digits.The best part is BMY is going to need a bigger oncology umbrella. That's because of its pending buyout of Celgene (NASDAQ:CELG). CELG's portfolio and pipeline of cancer drugs will fit perfectly with BMY's. While the integration and antitrust issues are taken a bit longer than expected, the deal is moving forward and when it's finally done, Bristol Meyers will have one of the best overall cancer portfolios around. This should lead to plenty of growth down the road. Especially when considering that the government may have little ability to regulate them. * 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar For income seekers, this could make BMY a top healthcare stock to buy for years' worth of dividend growth. Physicians Realty Trust (DOC)Source: Shutterstock Dividend Yield: 5.3%It's not just the drugs or equipment in a hospital that can pay some hefty dividends. The owners of the hospital itself could be the real income play. And that makes Physicians Realty Trust (NYSE:DOC) one of the best sleepier healthcare stocks to buy.DOC is a real estate investment trust (REIT) that owns 250 properties across 30 different states. The bulk of these -- around 93% of its total portfolio -- are medical office buildings. Medical office buildings are one of the more stable varieties of medical properties as they are generally constructed for this purpose only. Secondly, most of DOC's properties are signed to long-term leases and are located on major health campuses that are affiliated with leading health systems. This provides a very stable base of rental income for the REIT's bottom line.Even better is that 78% of DOC's portfolio is triple-net leased. This holy grail of leases means that tenants are responsible for paying items like taxes, maintenance and insurance costs. This provides better margins and cash flows for DOC's buildings. Those cash flows have been growing. since its IPO in 2013, DOC's FFO has grown by a staggering 195%. And while that torrid growth has slowed a bit in recent years, the healthcare stock still pumps out plenty of cash to fund its steady dividend. Moreover, DOC continues to use its strong balance sheet to perform smart M&A transactions to boost its portfolio further.In the end, Physicians Realty Trust is a great healthcare stock to add some yield to your portfolio. Cardinal Health (CAH)Source: Shutterstock Dividend Yield: 4.42%Truth be told, Cardinal Health (NYSE:CAH) has a few warts and isn't a pristine member of the best healthcare stocks club. The firm's two main lines of business -- drug distribution and medical devices -- aren't doing so hot right now. For one thing, the distributors are being taken down as they are the main targets of lower-price political punditry, while the kinds of devices it makes are directly in the line of fire from Medicare for All plans. Add in pending opioid legislation and Cardinal has been hit hard. Shares of CAH are around 23% lower from their peaks this year.But the drop has pushed shares into bargain territory. Today, CAH can be had for a P/E of under 10 and a dividend yield of 4.42%. That's dirt cheap, especially considering that its situation may not be that bad.For one thing, CAH is expected to see steady growth. As one of the space's largest distributors of drugs, including low-price generics, the firm has an entrenched position among hospitals and doctors. Cardinal did see its full-year revenues increase by 6% to a whopping $145.5 billion for fiscal 2019. And that leadership position throws off a lot of cash. Adding its low debt compared to peers and CAH has plenty of wiggle room to navigate the challenges, with a payout ratio of just 40%. Right now, it's priced as it won't be able to survive. That's just ridiculous. * 7 "Boring" Stocks With Exciting Prospects While it may seem like a risky play, CAH is priced cheap enough and it has a strong enough yield that it's worth the gamble. Becton Dickinson (BDX)Source: Shutterstock Dividend Yield: 1.25%On the surface, Becton Dickinson (NYSE:BDX) looks like one of the most boring healthcare stocks. That's because the firm is one of the largest producers of so-called sharps products. We're talking needles and syringes.BDX's product catalog spans everything from insulin needles and catheters to more advanced regional anesthesia and drug delivery products. The real win for Becton is that these items are one-time only products. Just like Baxter, hospitals and doctors have to keep calling their BDX sales rep for more. This niche produces ample cash flow and its integration of rival Bard only boosted its catalog further.But BDX isn't simply staying in its lane. In recent years, it has expanded its portfolio into some high-tech devices. This includes intravenous pumps, surgery products and even PCR/life science equipment. These divisions have been growing nicely and are starting to contribute significantly to Becton's bottom line.The best part is that BDX's ample cash flows are allowing it to pay down the debt it took out to buy Bard faster than expected. Management expects to use that future cash flows to fund tuck-in acquisitions, conduct buybacks and boost its dividend further. Already, BDX has grown its payout by 42% over the last five years.Given its steady revenues and future potential, BDX makes an ideal dividend growth play among the healthcare stocks.At the time of this writing, Aaron Levitt did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy on the Dip * 7 Marijuana Stocks With Critical Levels to Watch * 7 Internet of Things Stocks to Buy Now The post 5 Healthcare Stocks to Buy for Healthy Dividends appeared first on InvestorPlace.

  • 10 Most-Loved Stocks in Hedge Funds: Goldman's VIP List
    Investopedia

    10 Most-Loved Stocks in Hedge Funds: Goldman's VIP List

    Goldman Sachs’ “Hedge Fund VIP List”—containing the 50 most popular stocks among hedge fund portfolios—has outperformed the broader market for the past 18 years. The Hedge Fund VIP basket has beaten the market by an average 50 bps in every quarter since 2001. The list is a tool that investors can use to “follow the smart money,” wrote Goldman’s analysts in their most recent Hedge Fund Trend Monitor report, which analyzes a group of 835 distinct hedge funds.

  • The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
    Zacks

    The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

    The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

  • BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA
    Zacks

    BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA

    The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.

  • David Abrams Keeps Boosting Camping World, Gains 2 New Holdings in 2nd Quarter
    GuruFocus.com

    David Abrams Keeps Boosting Camping World, Gains 2 New Holdings in 2nd Quarter

    Klarman protégé releases quarterly portfolio, top buy is medical tech IPO company Continue reading...

  • Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
    Zacks

    Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More

    Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

  • BMY Stock Plus Celgene Will Be A Top 5 Pharma — But Should You Buy It?
    Investor's Business Daily

    BMY Stock Plus Celgene Will Be A Top 5 Pharma — But Should You Buy It?

    Pharmaceutical company Bristol-Myers has been in a downtrend since 2016 and after unveiling its merger with Celgene. Is now the right time to buy BMY stock?

  • Why The 2 Biggest Biotech Stocks Were Just Hit With Downgrades
    Investor's Business Daily

    Why The 2 Biggest Biotech Stocks Were Just Hit With Downgrades

    An analyst downgraded shares of biotechs Amgen and Celgene on Monday, saying both stocks are nearing appropriate values. Amgen stock ran up after a judge sided with it in a patent battle.

  • Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
    Zacks

    Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer

    Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.

  • 5 Biggest New Drug Approvals Potentially on the Way in 2019
    Motley Fool

    5 Biggest New Drug Approvals Potentially on the Way in 2019

    FDA approvals for these drugs could translate to billions of dollars for a few companies.

  • How Big Is Celgene's Latest Good News?
    Motley Fool

    How Big Is Celgene's Latest Good News?

    FDA approval of fedratinib could lead to significantly more revenue for the biotech. But even better news could be on the way.

  • Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
    Zacks

    Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?

    Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

  • Business Wire

    U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis

    INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer

  • Reuters

    UPDATE 2-FDA approves Celgene's bone marrow cancer treatment

    The U.S. Food and Drug Administration on Friday approved Celgene Corp's Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved drug to treat the disease. It will compete with Incyte Corp's Jakafi, also a JAK inhibitor, which was approved in 2011 for treating the same condition. Analysts said Inrebic's approval does not pose a meaningful threat to Jakafi, which generated $1.4 billion in revenue for Incyte in 2018.

  • Benzinga

    Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios

    The latest round of 13F filings from institutional investors were out this week, revealing to the world the stocks that some of the richest and most successful investors have been buying and selling. Takeaways ...

  • Seth Klarman's Baupost Boosts Liberty, Reduces eBay
    GuruFocus.com

    Seth Klarman's Baupost Boosts Liberty, Reduces eBay

    Baupost had a busy 2nd quarter, according to its 13-F filing Continue reading...

  • Agios Rides High on Tibsovo Sales Amid Acute Competition
    Zacks

    Agios Rides High on Tibsovo Sales Amid Acute Competition

    Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.

  • Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
    Zacks

    Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat

    Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.

  • 5 Top Cancer-Fighting Stocks to Buy Now
    Motley Fool

    5 Top Cancer-Fighting Stocks to Buy Now

    Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.

  • GuruFocus.com

    Seth Klarman Buys XPO Logistics, Exits 3 Positions in 2nd Quarter

    Baupost magnate also substantially increases Bristol-Myers Squibb Continue reading...

  • Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
    Zacks

    Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

    Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

  • Investing.com

    Stocks - Tilray, Canada Goose, Luckin Coffee Fall Premarket

    Investing.com - Stocks in focus in premarket trading on Wednesday:

  • Top Stock Reports: Micron, Sinopec, Celgene & More
    Zacks

    Top Stock Reports: Micron, Sinopec, Celgene & More

    Top Stock Reports: Micron, Sinopec, Celgene & More

  • Mergers & Acquisitions Take Center Stage in Biotech Industry
    Zacks

    Mergers & Acquisitions Take Center Stage in Biotech Industry

    Mergers & Acquisitions Take Center Stage in Biotech Industry

  • Financial Times

    JPMorgan Chase set to scoop record fee for Allergan sale

    JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Botox-maker Allergan on a planned $63bn sale to US pharmaceutical group AbbVie. the $120m paid to Morgan Stanley for advising US agribusiness Monsanto on its $66bn sale to Germany’s Bayer in 2016, according to data from Dealogic. The details of the fee arrangement were disclosed by Allergan this week as it prepares for a shareholder vote on its sale to Chicago-based AbbVie.